Clinical Trials Directory

Trials / Completed

CompletedNCT01329042

Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Ouiheng International Healthcare Co., Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone. Although providing good results, stone recurrence is usually found as the therapies do not change the underlying metabolic abnormality. Among the metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis. This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.

Conditions

Interventions

TypeNameDescription
DRUGPotassium-sodium citrateThe treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment

Timeline

Start date
2005-05-01
Primary completion
2007-10-01
Completion
2008-02-01
First posted
2011-04-05
Last updated
2011-04-05

Source: ClinicalTrials.gov record NCT01329042. Inclusion in this directory is not an endorsement.